Les conférenciers invités seront Dr. Julien Bissonnette et Dr. Angela Cheung. Rejoinez l’événement sur notre page facebook.
On November 25, 2019, CymaBay halted all clinical trials of seladelpar after atypical histologic findings with no clinical or laboratory correlates were identified at the planned end-of treatment biopsy review of a 52-week Phase 2 NASH study. The FDA concurred with this decision and placed all active INDs for seladelpar on clinical hold. CymaBay committed to an in-depth investigation of these findings and comprehensive safety evaluation that concluded with an independent, expert panel review involving some of the world’s leading liver pathologists and hepatologists. The expert panel found no clinical, biochemical or histological evidence of seladelpar-related liver injury in the Phase 2 NASH study and unanimously supported re-initiating clinical development of seladelpar pending approval by the FDA. Based on the results of the investigation and the expert panel conclusions, FDA concluded that clinical trials for NASH, PBC and PSC may resume.
Our Annual General Meeting will be held from 10:00 am to noon on April 25, 2020 Due to COVID-19 restrictions, the meeting will be held via conference call. At this meeting we will review the financial statements, vote for Executive & Board of Directors, and review the annual report for the Canadian PBC Society. For more information to join the meeting please register online.